Granules India Promoter sells 3.09 pecent stake for Rs 304 crore

Published On 2024-05-23 07:17 GMT | Update On 2024-05-23 07:18 GMT

Hyderabad: Krishna Prasad Chigurupati, a promoter of Granules India, has sold a 3.09 percent stake in the company for Rs 304 crore through an open market transaction. According to data from the NSE's block deal, Chigurupati sold 75 lakh shares of Granules India.

The shares were disposed of at an average price of Rs 405.08 apiece, taking the deal size to Rs 303.81 crore, as per the data on the National Stock Exchange (NSE).

According to a regulatory filing on Wednesday, Granules India said the primary objectives of the deal was to clear personal debt, to release the existing pledge on his holding in the company, and creating a small personal liquidity.

Chigurupati further notified the company that he has no plans to sell his shareholding in Granules India Ltd in the foreseeable future.

"Post this transaction, the total promoter & promoter group shareholding in the company has changed from 41.96 per cent to 38.87 per cent of the paid-up equity share capital of the company," the BSE filing said.

Dr. Krishna Prasad Chigurupati’s holding as a Promoter of the Company has changed from 34.78 % to 31.69 % of the Paid-up equity share capital of the Company.

According to PTI, Axis Mutual Fund, Dendana Investments (Mauritius), Fidelity Funds India Focus Fund, Fidelity India Fund, Fidelity Korea - India Equity Investment Trust-Mother and Long Term Equity Fund were among the buyers of shares of Granules India.

Massachusetts Institute of Technology, and Mumbai-based Old Bridge Capital Management also picked up the shares of the company, as per the block data on the NSE.

Granules India Limited, incorporated in 1991 is a vertically integrated Indian pharmaceutical company headquartered in Hyderabad. The Company is among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). Its products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, U.S. and U.K. The Company has 7 manufacturing facilities out of which 6 are located in India and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.

Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Granules India Promoter sells 3.09 pecent stake for Rs 304 crore

Similar News